Skip to content

Depression: all studies

Page 699 of 1,034: studies 6,981 to 6,990 of 10,336, newest first. Back to the depression overview

Research

Characteristics of poisonings involving ketamine in the United States, 2019-2021.

Journal of Psychopharmacology August 2023 Joseph J Palamar, Nicole D. Fitzgerald, David J Grundy et al.

The use of ketamine, a controlled dissociative anesthetic, has become more widespread in recent years with recreational/nonmedical use increasing and ketamine becoming more widely available in clinics to treat depression. We examined recent trends in adverse effects related to ketamine use. US National Poison Control data were examined, focusing on ketamine exposures among those aged ⩾13...

SAINDO DO ESTIGMA: PSICODÉLICOS COMO ALTERNATIVA VIÁVEL NA PROMOÇÃO DA SAÚDE MENTAL

August 1, 2023 Gabriel Alexandre Moura, ANA Cecilia de Carvalho Cunha, Beatriz Barros Cordeiro et al.

Objetivo: O uso de psicodélicos em psicoterapia tem sido objeto de interesse crescente na última década.Portanto, o objetivo desta revisão sistemática é examinar a literatura científica mais recente sobre os benefícios do uso de psicodélicos na promoção da saúde mental.Metodologia: Os descritores para essa pesquisa foram selecionados pela Descritores em ciência da saúde (DeCS/MeSH), da...

HCN channel inhibitor induces ketamine-like rapid and sustained antidepressant effects in chronic social defeat stress model

Neurobiology of Stress August 1, 2023 Min Cai, Yingbo Zhu, M. R. Shanley et al.

Repeated, long-term (weeks to months) exposure to standard antidepressant medications is required to achieve treatment efficacy. In contrast, acute ketamine quickly improves mood for an extended time. Recent work implicates that hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are involved in mediating ketamine's antidepressant effects. In this study, we directly targeted HCN...

Sudarshan Kriya Meditation Reduces Substance Abuse Cravings and Improves Physical and Emotional Well-Being of Individuals With Opioid Use Disorder: A Pilot Study.

Journal of Psychosocial Nursing and Mental Health Services August 1, 2023 Sathya Dev Unudurthi, Kathy D Wright, Jill M Klimpel et al. 4 citations

Opioid use disorder (OUD) is widely prevalent in the United States and there are high levels of comorbidity between OUD and mental illnesses, such as depression, anxiety, and posttraumatic stress disorder. Psychotherapy, in addition to medication-assisted therapy, are considered important components of long-term OUD treatment. Sudarshan Kriya Yoga (SKY) is a breathing-based mind-body...

Mindfulness or meditation therapy for Parkinson's disease: A systematic review and meta-analysis of randomized controlled trials.

European Journal of Neurology August 1, 2023 Ho-Wei Lin, Ka-Wai Tam, Yi-Chun Kuan 16 citations

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Mindfulness and meditation therapies have been demonstrated as effective alternative treatments for patients with neurological disorders. However, the effects of mindfulness and meditation therapies on PD remain unclear. This meta-analysis investigated the effects of mindfulness and meditation therapies in...

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice.

Neuropsychopharmacology August 1, 2023 Sarah J. Jefferson, Ian Gregg, Mark Dibbs et al. 57 citations

Serotonergic psychedelics are gaining increasing interest as potential therapeutics for a range of mental illnesses. Compounds with short-lived subjective effects may be clinically useful because dosing time would be reduced, which may improve patient access. One short-acting psychedelic is 5-MeO-DMT, which has been associated with improvement in depression and anxiety symptoms in early phase...

Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.

Palliative & Supportive Care August 1, 2023 Xuepeng Jing, Nicholas Hoeh, David B Menkes 18 citations

People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidence has stimulated interest in the therapeutic use of psychedelics at end of life. Much uncertainty remains, however, mainly due to methodological difficulties that beset existing trials. We conducted a scoping review of pipeline clinical trials of psychedelic treatment...

"A ghost doesn't need insulin," Cotard's delusion leading to diabetic ketoacidosis and a body-mass index of 15: a case presentation.

BMC Psychiatry July 31, 2023 Christopher Robertson, Thomas J. Dunn

Cotard's Syndrome (CS) is a rare clinical entity where patients can report nihilistic, delusional beliefs that they are already dead. Curiously, while weight loss, dehydration, and metabolic derangements have been described as discussed above, a review of the literature revealed neither a single case of a severely underweight patient nor a serious metabolic complication such as Diabetic...

DOI: 10.1186/s12888-023-05039-6 (opens in new tab) Full text (opens in new tab) Anorexia nervosa Case report Cotard’s delusion Dka

All-natural 5-MeO-DMT sigma receptor 1 agonist and its therapeutic impact in mental and neurodegener-ative diseases through mitochondrial activation

Science Reviews Biology July 30, 2023 Milena Batalla 2 citations

The sigma-1 receptor S1R is a chaperone that resides mainly at the mitochondrion-associated endoplasmic reticulum ER membrane MAM, it is considered a “pluripotent modulator” in living systems, plays a critical role in maintaining neuronal homeostasis and acts as a dynamic pluripotent modulator in living systems. Given its specific localization at the MAM, S1R plays a major role regulating...

DOI: 10.57098/scirevs.biology.2.2.1 (opens in new tab) Sigma-1 receptor Epigenetics Mitochondrion Agonist +2

Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial

Cannabis and Cannabinoid Research July 26, 2023 Valentina Lorenzetti, Eugene McTavish, Samantha J Broyd et al.

Introduction: Cannabis use is associated with brain functional changes in regions implicated in prominent neuroscientific theories of addiction. Emerging evidence suggests that cannabidiol (CBD) is neuroprotective and may reverse structural brain changes associated with prolonged heavy cannabis use. In this study, we examine how an ∼10-week exposure of CBD in cannabis users affected...